ClinicalTrials.Veeva

Menu

A Randomized Controlled Trial Evaluating One Drop | Premium With Afrezza vs. One Drop | Premium Alone

I

Informed Data Systems

Status and phase

Unknown
Phase 4

Conditions

Diabetes Mellitus, Type 2

Treatments

Drug: Afrezza plus One Drop | Premium
Other: One Drop | Premium

Study type

Interventional

Funder types

Industry

Identifiers

Details and patient eligibility

About

The A-One study is a prospective, randomized controlled trial evaluating the use of the One Drop | Premium 'On Track' in combination with Afrezza treatment on the glycemic control, treatment adherence, social-cognitive barriers to adherence, and treatment satisfaction of people with Type 2 diabetes (T2D) and a hemoglobin A1c (A1c) > 7.0% already prescribed an injectable rapid-acting insulin.

Full description

Eligible participants (N=400) with an A1c > 7.0% already prescribed a rapid-acting insulin will be randomized to one of two groups: (1) One Drop | Premium 'On Track' (i.e., use the One Drop | Mobile app with in-app diabetes education accredited by the American Diabetes Association with supplemental Afrezza content and a live Certified Diabetes Educator messaging in the app, the 'Chrome' Bluetooth-connected blood glucose meter that uploads blood glucose values in the app, and 150 test strips per month) in combination with Afrezza treatment (n=200) or (2) One Drop | Premium 'On Track' plus their current rapid-acting insulin (n=200).

Enrollment

400 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • 18-75 years of age
  • Self-reported diagnosis of T2D
  • Diagnosed with diabetes for at least 12 months
  • Prescribed a prandial rapid-acting insulin
  • Willing to take Afrezza rapid-acting insulin for 3 months instead of current rapid-acting insulin
  • Willing to get a physician's prescription for Afrezza
  • Self-reported A1c > 7.0% (later confirmed with a mail-in A1c laboratory test)
  • Owns and uses an iPhone or Android phone with an operating system compatible with the One Drop | Mobile app
  • Has successfully downloaded and used a smart phone application previously

Exclusion criteria

  • Currently pregnant or planning to become pregnant during the trial period
  • Cannot read or write in English
  • Currently in a diabetes education or coaching program
  • Had previously used One Drop | Premium or One Drop |
  • Experts coaching
  • Had previously used or is currently using Afrezza
  • Currently smokes (cigaretts, e-cigs, pipes, cigars, marijuana) or has smoked anytime in the past 6 months
  • Has chronic lung disease, e.g., COPD and asthma

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

400 participants in 2 patient groups

One Drop | Premium with Afrezza
Active Comparator group
Treatment:
Drug: Afrezza plus One Drop | Premium
One Drop | Premium without Afrezza
Other group
Treatment:
Other: One Drop | Premium

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems